natgillin/translations-raw huggingface dataset:
Hvis din læge beslutter at stoppe behandlingen med et af de aktive stoffer i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, kan du få efavirenz, emtricitabin og/eller tenofovirdisoproxil hver for sig eller sammen med anden medicin til behandling af din hiv-infektion. 
If your doctor decides to stop one of the components of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, you may be given efavirenz, emtricitabine and/or tenofovir disoproxil separately or with other medicines for the treatment of your HIV infection.
Cmax: ↓ 45 % (CYP3A4 eller P-gp-induktion - virkning på elbasvir) 
Cmax: ↓ 45% (CYP3A4 or P-gp induction - effect on elbasvir)
Det bør også overvejes at afbryde behandlingen med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i tilfælde af progressiv forværring af nyrefunktionen, når der ikke er identificeret andre årsager. 
Interrupting treatment with Efavirenz/Emtricitabine /Tenofovir disoproxil Krka should also be considered in case of progressive decline of renal function when no other cause has been identified.
Efavirenz, som er et af de aktive stoffer i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, kan blive i blodet i et stykke tid efter, at behandlingen er stoppet. 
Efavirenz, one of the active components of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, may remain in your blood for a time after therapy is stopped.
Hvis du har en alvorlig leversygdom, må du ikke tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (se ovenfor punkt 2, Tag ikke Efavirenz/Emtricitabine/Tenofovir disoproxil Krka). 
If you have severe liver disease, do not take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (see earlier in section 2, Do not take Efavirenz/Emtricitabine/Tenofovir disoproxil Krka).
Farmakoterapeutisk klassifikation: Antivirale midler til systemisk brug, Antivirale lægemidler til behandling af hiv-infektioner, kombinationer. 
Pharmacotherapeutic group: Antiviral for systemic use, antivirals for treatment of HIV infections, combinations, ATC code: J05AR06.
-3,3% (-8,3% til 2,7%) 
-3.3 (-8.3% to 2.7%)
Samtidig administration af efavirenz og voriconazol standarddoser er kontraindiceret. 
Co-administration of standard doses of efavirenz and voriconazole is contraindicated.
De kan forekomme hyppigere, hvis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka indtages sammen med et måltid, muligvis pga. øget plasmakoncentration for efavirenz (se pkt. 
They may occur more frequently when Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is taken concomitantly with meals possibly due to increased efavirenz plasma levels (see section 5.2).
Levonorgestrel (aktiv metabolit): AUC: ↓ 83% (↓ 79 til ↓ 87) Cmax: ↓ 80% (↓ 77 til ↓ 83) Cmin: ↓ 86% (↓ 80 til ↓ 90) (induktion af metabolisme) 
Levonorgestrel (active metabolite): AUC: ↓ 83% (↓ 79 to ↓ 87) Cmax: ↓ 80% (↓ 77 to ↓ 83) Cmin: ↓ 86% (↓ 80 to ↓ 90) (induction of metabolism)
Hvis seponering af behandling med en af komponenterne i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er indiceret, eller hvis dosismodificering er påkrævet, er separate efavirenz-, emtricitabin- og tenofovirdisoproxil-præparater tilgængelige. 
Where discontinuation of therapy with one of the components of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is indicated or where dose modification is necessary, separate preparations of efavirenz, emtricitabine and tenofovir disoproxil are available.
Brug af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka til børn og unge er ikke blevet undersøgt. 
The use of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka in children and adolescents has not been studied.
Cmax: ↓ 87 % (CYP3A4 eller P-gp-induktion - virkning på grazoprevir) 
Cmax: ↓ 87% (CYP3A4 or P-gp induction - effect on grazoprevir)
Når de to strata blev analyseret separat, var responsraterne i det stratum med tidligere proteasehæmmer-behandling numerisk lavere for de patienter, der skiftede til efavirenz/emtricitabin/tenofovirdisoproxil [92,4% versus 94,0% for PVR (sensitivitetsanalyse) for henholdsvis efavirenz/emtricitabin/tenofovirdisoproxil- og SBR-patienter (SBR, stayed on their baseline regimen); en forskel (95% CI) på 1,6% (10,0%; 6,7%)]. 
When the two strata were analysed separately, response rates in the stratum with prior PI-treatment were numerically lower for patients switched to efavirenz/emtricitabine/tenofovir disoproxil [92.4% versus 94.0% for the PVR (sensitivity analysis) for efavirenz/emtricitabine/tenofovir disoproxil and SBR patients respectively; a difference (95%CI) of -1.6% (-10.0%, 6.7%).
Behandlingen bør ikke seponeres hos patienter med fremskreden leversygdom eller levercirrose, da forværringen efter behandlingen kan føre til hepatisk dekompensation. 
In patients with advanced liver disease or cirrhosis, treatment discontinuation is not recommended since post-treatment exacerbation of hepatitis may lead to hepatic decompensation.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka tages normalt ikke sammen med anden medicin, som kan skade dine nyrer (se Brug af anden medicin sammen med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka). 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not usually taken with other medicines that can damage your kidneys (see Other medicines and Efavirenz/Emtricitabine/Tenofovir disoproxil Krka).
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bør ikke anvendes til patienter, som har haft en livstruende hudreaktion (f.eks. Stevens-Johnsons syndrom) under NNRTI-behandling. 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is not recommended for patients who have had a life-threatening cutaneous reaction (e.g., Stevens-Johnson syndrome) while taking an NNRTI.
Den gennemsnitlige plasma/blod koncentrationsratio var ca. 1,0 og den gennemsnitlige sæd/plasma koncentrationsratio var ca. 4,0. 
and the mean semen to plasma concentration ratio was approximately 4.0.
Da anvendelse af to NNRTIere ikke viste sig at være gavnligt mht. virkning og sikkerhed anbefales samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og en anden NNRTIer ikke. 
Since use of two NNRTIs proved not beneficial in terms of efficacy and safety, co-administration of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka and another NNRTI is not recommended.
Nyresvigt (akut og kronisk), akut tubulær nekrose, nefritis (herunder akut interstitiel nefritis) 
Rare renal failure (acute and chronic), acute tubular necrosis,
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka anvendes sammen med lavdosis ritonavir, bør muligheden for øget forekomst af efavirenzassocierede bivirkninger overvejes pga. mulig farmakodynamisk interaktion. 
When using Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka with low-dose ritonavir, the possibility of an increase in the incidence of efavirenz-associated adverse events should be considered, due to possible pharmacodynamic interaction.
Når det blev anvendt i kombination med efavirenz og to NRTIer, gav lopinavir/ritonavir 533/133 mg (bløde kapsler) to gange dagligt de samme lopinavirplasma-koncentrationer sammenlignet med lopinavir/ritonavir (bløde 
When used in combination with efavirenz and two NRTIs, 533/133 mg lopinavir/ritonavir (soft capsules) twice daily yielded similar lopinavir plasma concentrations as compared to lopinavir/ritonavir (soft capsules) 400/100 mg twice daily without efavirenz (historical data).
Hvis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka skal anvendes sammen med darunavir/ritonavir, bør regimet med darunavir/ritonavir 600/100 mg to gange dagligt anvendes. 
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is to be used in combination with darunavir/ritonavir, the darunavir/ritonavir 600/100 mg twice daily regimen should be used.
Tabletkerne: mikrokrystallinsk cellulose, hydroxypropylcellulose, natriumlaurilsulphat, croscarmellosenatrium, rød jernoxid (E172), magnesiumstearat, natriumstearylfumarat. 
Tablet core: microcrystalline cellulose, hydroxypropylcellulose, sodium laurilsulfate, croscarmellose sodium, ferric oxide red (E172), magnesium stearat, sodium stearyl fumarate.
Patienter med let leversygdom (Child-Pugh-Turcotte (CPT), klasse A) kan behandles med den dosis, der normalt anbefales for Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (se pkt. 
Patients with mild liver disease (Child-Pugh-Turcotte (CPT), Class A) may be treated with the normal recommended dose of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka (see sections 4.3, 4.4 and 5.2).
Carbamazepin kan nedsætte mængden af efavirenz, der er et af de aktive stoffer i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, i blodet. 
Carbamazepine can reduce the amount of efavirenz, one of the components of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, in your blood.
Efavirenz/emtricitabine/tenofovirdisoproxil er ikke blevet undersøgt hos patienter over 65 år. 
Efavirenz/emtricitabine/tenofovir disoproxil has not been studied in patients over the age of 65.
Mht. samtidig administration af efavirenz og lavdosis ritonavir i kombination med en proteasehæmmer se afsnittet om ritonavir ovenfor. 
For coadministration of efavirenz with low-dose ritonavir in combination with a protease inhibitor, see section on ritonavir above.
Symptomerne på din hepatitis kan blive værre, efter du er holdt med at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka. 
Symptoms of your hepatitis may become worse after discontinuation of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Der foreligger ingen data om sikkerheden og virkningen af efavirenz/emtricitabine/tenofovir disoproxil i kombination med andre antiretrovirale lægemidler. 
No data are available on the safety and efficacy of efavirenz/emtricitabine/tenofovir disoproxil in combination with other antiretroviral agents.
De fleste tilfælde forekom hos patienter, der allerede havde en leversygdom, men der har været nogle få indberetninger fra patienter uden allerede eksisterende leversygdom. 
Most cases occurred in patients who already had liver disease, but there have been a few reports in patients without any existing liver disease inflammation of the kidney, passing a lot of urine and feeling thirsty back pain caused by kidney problems, including kidney failure.
AUC: ↔*/** (↓ 10% til ↑ 26%) Cmax: ↔*/** (↓ 5% til ↑ 26%) Cmin: ↑ 12%*/** (↓ 16 til ↑ 49) (CYP3A4-induktion). 
AUC: ↔*/** (↓ 10% to ↑ 26%) Cmax: ↔*/** (↓ 5% to ↑ 26%) Cmin: ↑ 12%*/** (↓ 16 to ↑ 49) (CYP3A4 induction).
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka filmovertrukne tabletter er lys orange-lyserøde ovale, bikonvekse, filmovertrukne tabletter med skrå kanter. 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka film-coated tablets are light orange pink, oval, biconvex, film-coated tablets with beveled edges.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka må ikke administreres sammen med terfenadin, astemizol, cisaprid, midazolam, triazolam, pimozid, bepridil eller ergotalkaloider (f.eks. ergotamin, dihydroergotamin, ergonovin og methylergonovin), da hæmning af disses metabolisme kan føre til alvorlige livstruende hændelser (se pkt. 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka must not be administered concurrently with terfenadine, astemizole, cisapride, midazolam, triazolam, pimozide, bepridil, or ergot alkaloids (for example, ergotamine, dihydroergotamine, ergonovine, and methylergonovine), since inhibition of their metabolism may lead to serious, life-threatening events (see section 4.3).
Hyperglykæmi, hypertriglyceridæmi 
Common hypertriglyceridaemia hyperglycaemia, hypertriglyceridaemia
Fortæl det til lægen hvis du tager anden medicin, som kan skade dine nyrer, f.eks.: Eksempler inkluderer: 
Tell your doctor if you are taking other medicines which may damage your kidneys.
Overfølsomhed Metabolisme og ernæring: Meget almindelig 
Metabolism and nutrition disorders: Very common hypophosphataemia
Behandlingsgruppe Efavirenz/emtricitabin/tenofovirdisopr oxil (N=203) n/N (%) 
Treatment group Efavirenz/emtricitabine/tenofovir disoproxil (N=203) n/N (%)
Du bør heller ikke tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka sammen med anden medicin, der indeholder efavirenz (medmindre din læge anbefaler det), emtricitabin, tenofovirdisoproxil, tenofoviralafenamid, lamivudin eller adefovirdipivoxil. 
Also, Efavirenz/Emtricitabine/Tenofovir disoproxil Krka should not be taken with any other medicines that contain efavirenz (unless recommended by your doctor), emtricitabine, tenofovir disoproxil, tenofovir alafenamide, or lamivudine or adefovir dipivoxil.
Hiv renal uddannelsesbrochure, herunder lineal med to skalaer til beregning af kreatininclearance 
The Summary of Product Characteristics HIV renal educational brochure, including the creatinine clearance slide ruler
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kan nedsætte mængden af atovaquon/proguanil eller artemether/lumefantrin i blodet. 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may reduce the amount of atovaquone/proguanil or artemether/lumefantrine in your blood.
Når Efavirenz/Emtricitabine/Tenofovir disoproxil Krka tages sammen med rifampicin hos patienter, der vejer 50 kg eller derover, kan yderligere 200 mg/dag (800 mg i alt) efavirenz give samme eksponering som en daglig efavirenzdosis på 600 mg, når det tages uden rifampicin. 
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka is taken with rifampicin in patients weighing 50 kg or greater, an additional 200 mg/day (800 mg total) of efavirenz may provide exposure similar to a daily efavirenz dose of 600 mg when taken without rifampicin.
Hvis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka administreres sammen med et NSAID, skal nyrefunktionen monitoreres på tilstrækkelig vis. 
If Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is co-administered with an NSAID, renal function should be monitored adequately.
Der var ingen klinisk signifikante farmakokinetiske interaktioner, når tenofovirdisoproxil blev administreret samtidig med saquinavir forstærket med ritonavir. 
There were no clinically significant pharmacokinetic interactions when tenofovir disoproxil was co-administered with ritonavir boosted saquinavir.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka skal tages hver dag. 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka must be taken every day.
Hos hiv-inficerede patienter, som samtidig er inficeret med HBV, kan der fremkomme klinisk og laboratoriemæssig evidens for hepatitis efter seponering af behandlingen (se pkt. 
Exacerbations of hepatitis after discontinuation of treatment In HIV infected patients co-infected with HBV, clinical and laboratory evidence of hepatitis may occur after discontinuation of treatment (see section 4.4).
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka skal seponeres hos patienter, der udvikler svært udslæt ledsaget af blæredannelse, afskalning, mucosa-påvirkning eller feber. 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka must be discontinued in patients developing severe rash associated with blistering, desquamation, mucosal involvement or fever.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, bør en alternativ antimykotisk behandling overvejes. 
Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka, an alternative antifungal treatment should be considered.
Fås i pakninger, der indeholder 1 flaske med 30 filmovertrukne tabletter og 90 (3 flasker med 30) filmovertrukne tabletter. 
The following pack sizes are available: cartons containing 1 bottle of 30 film-coated tablets or 90 (3 bottles of 30) film-coated tablets.
Reference: Enkeltdosis 600 mg efavirenztablet, 200 mg emtricitabinkapsel og 245 mg tenofovirdisoproxiltablet taget under faste. 
Reference: single dose of a 600 mg efavirenz tablet, 200 mg emtricitabine capsule and 245 mg tenofovir disoproxil tablet taken under fasted conditions.
Norelgestromin (aktiv metabolit): AUC: ↓ 64% (↓ 62 til ↓ 67) Cmax: ↓ 46% (↓ 39 til ↓ 52) Cmin: ↓ 82% (↓ 79 til ↓ 85) 
Norelgestromin (active metabolite): AUC: ↓ 64% (↓ 62 to ↓ 67) Cmax: ↓ 46% (↓ 39 to ↓ 52) Cmin: ↓ 82% (↓ 79 to ↓ 85)
Hvis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka bruges samtidig med nefrotoksiske lægemidler, skal nyrefunktionen nøje monitoreres i henhold til det anbefalede skema. 
If Efavirenz/Emtricitabine /Tenofovir disoproxil Krka is used with nephrotoxic medicinal products, renal function should be closely monitored according to the recommended schedule.
Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka med elbasvir/grazoprevir er kontraindiceret, da det kan medføre tab af det virologiske respons på elbasvir/grazoprevir. 
Co-administration of efavirenz/emtricitabine/tenofovir disoproxil with elbasvir/grazoprevir is contraindicated because it may lead to loss of virologic response to elbasvir/grazoprevir.
Symptomer fra nervesystemet er almindelige med efavirenz, et af de aktive stoffer i Efavirenz/Emtricitabine/Tenofovir disoproxil Krka. 
Nervous system symptoms are common with efavirenz, one of the components of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
I et 144-ugers åbent, randomiseret, klinisk studie (GS-01-934), hvor antiretroviralt-behandlingsnaive hiv-1-inficerede patienter enten fik et regime en gang dagligt af efavirenz/emtricitabin/tenofovirdisoproxil eller en fast kombination af lamivudin og zidovudin, som blev givet to gange dagligt og efavirenz en gang dagligt (se produktresuméet for efavirenz/emtricitabin/tenofovirdisoproxil). 
In a 144-week open-label randomised clinical study (GS-01-934) antiretroviral treatment-naïve HIV-1 infected patients received either a once-daily regimen of efavirenz, emtricitabine and tenofovir disoproxil or a fixed combination of lamivudine and zidovudine administered twice daily and efavirenz once daily (please refer to the Summary of Product Characteristics for emtricitabine/tenofovir disoproxil).
Aminoglykosider, vancomycin (mod bakterieinfektioner) Foscarnet, ganciclovir, cidofovir (mod virusinfektioner) Amphotericin B, pentamidin (mod svampeinfektioner) interleukin-2 (til behandling af kræft), 
Some examples include: aminoglycosides, vancomycin (medicines for bacterial infections) foscarnet, ganciclovir, cidofovir (medicines for viral infections) amphotericin B, pentamidine (medicines for fungal infections) interleukin-2 (to treat cancer) non-steroidal anti-inflammatory drugs (NSAIDs, to relieve bone or muscle pains)
Hvis du holder op med at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka, skal du kontakte din læge, før du begynder at tage Efavirenz/Emtricitabine/Tenofovir disoproxil Krka-tabletter igen. 
If Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is stopped, speak to your doctor before you restart taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka tablets.
Fuldbyrdet selvmord vrangforestillinger neuroser 
Rare completed suicide delusion
Hvis du kaster op (inden for en time efter du har taget Efavirenz/Emtricitabine/Tenofovir disoproxil Krka), bør du tage en ny tablet. 
If you throw up the tablet (within 1 hour after taking Efavirenz/Emtricitabine/Tenofovir disoproxil Krka), you should take another tablet.
Det forudses, at tenofovir-eksponeringen (AUC) vil være ca. 30% lavere efter administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka på tom mave sammenlignet med tenofovirdisoproxil, når denne tages som individuel komponent sammen med mad (se pkt. 
It is anticipated that tenofovir exposure (AUC) will be approximately 30% lower following administration of efavirenz/emtricitabine/tenofovir disoproxil on an empty stomach as compared to the individual component tenofovir disoproxil when taken with food (see section 5.1).
Anvendelse af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka i kombination med saquinavir som den eneste protease-hæmmer frarådes. 
Use of Efavirenz/Emtricitabine/Tenofovi r disoproxil Krka in combination with saquinavir as the sole protease inhibitor is not recommended.
Der kræves ingen dosisjustering. 
No dose adjustment is recommended.
3, svært udslæt (<1%) 
3, dizziness (8.5%)
Graviditet bør undgås hos kvinder, der får Efavirenz/Emtricitabine/Tenofovir disoproxil Krka. 
Pregnancy should be avoided in women receiving Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka er kontraindiceret ved samtidig brug af lægemidler, som vides at forlænge QTc-intervallet og kan føre til Torsade de Pointes, f.eks. antiarytmika af klasse IA og III, neuroleptika og antidepressiva, visse antibiotika, herunder nogle stoffer af følgende klasser: makrolider, fluorokinoloner, imidazol- og triazol-antimykotika, visse nonsederende antihistaminer (terfenadin, astemizol), cisaprid, flecainid, visse antimalariamidler og methadon (sepkt. 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is contraindicated with concomitant use of drugs that are known to prolong the QTc interval and could lead to Torsade de Pointes, such as: antiarrhythmics of classes IA and III, neuroleptics and antidepressant agents, certain antibiotics including some agents of the following classes: macrolides, fluoroquinolones, imidazole, and triazole antifungal agents, certain non-sedating antihistaminics (terfenadine, astemizole), cisapride, flecainide, certain antimalarials and methadone (see section 4.3).
Da Efavirenz/Emtricitabine/Tenofovir disoproxil Krka indeholder efavirenz, emtricitabin og tenofovirdisoproxil, kan interaktioner, som er identificeret med disse lægemidler individuelt, opstå med Efavirenz/Emtricitabine/Tenofovir disoproxil Krka. 
As Efavirenz/Emtricitabine/Tenofovir disoproxil Krka contains efavirenz, emtricitabine and tenofovir disoproxil, any interactions that have been identified with these agents individually may occur with Efavirenz/Emtricitabine/Tenofovir disoproxil Krka.
Leversvigt med efavirenz 
Hepatic failure with efavirenz
Samtidig administration af Efavirenz/Emtricitabine/Tenofovir disoproxil Krka og didanosin anbefales ikke, da det resulterer i en stigning i systemisk eksponering for didanosin på 40-60%, hvilket kan øge risikoen for didanosin-relaterede bivirkninger (se pkt. 
Interaction with didanosine Co-administration of Efavirenz/Emtricitabine/Tenofovir disoproxil Krka and didanosine is not recommended as it results in a 40-60% increase in systemic exposure to didanosine that may increase the risk of didanosine-related adverse reactions (see section 4.5).
Almene symptomer og reaktioner på administrationsstedet Meget almindelig 
General disorders and administration site conditions: Very common asthenia
Patienter må ikke tidligere have oplevet virologisk svigt under antiretroviral behandling, og de må ikke før deres første antiretrovirale behandling have haft virustammer med mutationer, der kan give signifikant resistens over for en eller flere af de tre komponenter, som Efavirenz/Emtricitabine/Tenofovir disoproxil Krka indeholder (se pkt. 
Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Krka prior to initiation of their first antiretroviral treatment regimen (see sections 4.4 and 5.1).
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka kan påvirke virkningen af anden medicin, herunder naturlægemidler med Ginkgo bilobaekstrakt (tempeltræekstrakt). 
Efavirenz/Emtricitabine/Tenofovir disoproxil Krka may interact with other medicines, including herbal preparations such as Ginkgo biloba extracts.
Dosisjustering: Hvis Efavirenz/Emtricitabine/Tenofovir disoproxil Krka gives samtidigt med rifampicin til patienter, der vejer 50 kg eller derover, kan det overvejes at give yderligere 200 mg efavirenz/dag (800 mg i alt) (se pkt. 
Dose adjustment: If Efavirenz/Emtricitabine/Tenofovir disoproxil Krka is co-administered with rifampicin to patients weighing 50 kg or more, an additional 200 mg/day (800 mg total) of efavirenz may be considered (see section 4.5).
Mht. samtidig administration af efavirenz og lavdosis ritonavir i kombination med en protease-hæmmer se afsnittet om ritonavir nedenfor. 
For co-administration of efavirenz with lowdose ritonavir in combination with a protease inhibitor, see section on ritonavir below.